At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03692 HANSOH PHARMA
Not Yet Opened 10-12 16:08:17
31.560
+0.020
+0.06%
High32.580Low31.540Vol5.08M
Open31.540D1 Closing31.540Amplitude3.30%
Mkt Cap191.38BTradable Cap191.38BTotal Shares6.06B
T/O161.24MT/O Rate0.08%Tradable Shares6.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hansoh Pharma's Aumolertinib Application Validated by EMA for EU Review
MT Newswires Live  ·  10-12 09:04
Hansoh Pharma's Aumolertinib Application Validated by EMA for EU Review
Hansoh Pharmaceutical Says it Resubmitted EU Marketing Authorization Application for Aumolertinib to Ema
THOMSON REUTERS  ·  10-11 18:45
Hansoh Pharmaceutical Says it Resubmitted EU Marketing Authorization Application for Aumolertinib to Ema
Hansoh Pharmaceutical Says EMA Starts Reviewing Marketing Authorization Application for Aumolertinib
Reuters  ·  10-11 18:45
Hansoh Pharmaceutical Says EMA Starts Reviewing Marketing Authorization Application for Aumolertinib
Hansoh Pharmaceutical Group Stock Sheds 2.0% in Hong Kong
Dow Jones  ·  10-09
Hansoh Pharmaceutical Group Stock Sheds 2.0% in Hong Kong
Hansoh Pharmaceutical Group Stock Falls 5.1% in Hong Kong
Dow Jones  ·  10-08
Hansoh Pharmaceutical Group Stock Falls 5.1% in Hong Kong
Movement Alert｜HANSOH PHARMA Falls 3.01% in Regular Trading, Major Shareholder Affiliates Reduced Stakes and EU Marketing Revocation for Aumolertinib
Market Focus  ·  10-08
Movement Alert｜HANSOH PHARMA Falls 3.01% in Regular Trading, Major Shareholder Affiliates Reduced Stakes and EU Marketing Revocation for Aumolertinib
Does China Cancer Drug Filing Change The Bull Case For Hansoh Pharmaceutical Group (SEHK:3692)?
Simply Wall St.  ·  10-07
Does China Cancer Drug Filing Change The Bull Case For Hansoh Pharmaceutical Group (SEHK:3692)?
Hansoh Pharmaceutical Group Stock Rises 1.7% in Hong Kong
Dow Jones  ·  10-06
Hansoh Pharmaceutical Group Stock Rises 1.7% in Hong Kong
Cantrust (Far East) Limited Cuts Stake in Hansoh Pharma (03692) by 124,000 Shares at About HK$33.96 Each
Stock News  ·  10-05
Cantrust (Far East) Limited Cuts Stake in Hansoh Pharma (03692) by 124,000 Shares at About HK$33.96 Each
HANSOH PHARMA: JQC International Limited Disposes of Shares, Long Position Falls to 15.16%
HK Disclosure  ·  10-05
HANSOH PHARMA: JQC International Limited Disposes of Shares, Long Position Falls to 15.16%
HANSOH PHARMA: Junda Cen Disposes of Shares, Long Position Falls to 15.16%
HK Disclosure  ·  10-05
HANSOH PHARMA: Junda Cen Disposes of Shares, Long Position Falls to 15.16%
HANSOH PHARMA: APEX MEDICAL COMPANY LTD. Disposes of Shares, Long Position Falls to 15.16%
HK Disclosure  ·  10-05
HANSOH PHARMA: APEX MEDICAL COMPANY LTD. Disposes of Shares, Long Position Falls to 15.16%
HANSOH PHARMA: JQC Holding Limited Disposes of Shares, Long Position Falls to 15.16%
HK Disclosure  ·  10-05
HANSOH PHARMA: JQC Holding Limited Disposes of Shares, Long Position Falls to 15.16%
Hansoh Pharma Says Phase III Lighten Trial Shows 19.3% Weight Loss at Week 48 with Olatorepatide 15 Mg
Reuters  ·  10-05
Hansoh Pharma Says Phase III Lighten Trial Shows 19.3% Weight Loss at Week 48 with Olatorepatide 15 Mg
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02
Major Drugmakers Turn to China for Licensing Deals
Hansoh Pharmaceutical Group Stock Slips 3.3% in Hong Kong
Dow Jones  ·  10-02
Hansoh Pharmaceutical Group Stock Slips 3.3% in Hong Kong
Hansoh Pharmaceutical Group (SEHK:3692) Could Be 30% Undervalued On Late Stage Drug Progress
Simply Wall St.  ·  10-02
Hansoh Pharmaceutical Group (SEHK:3692) Could Be 30% Undervalued On Late Stage Drug Progress
Movement Alert｜HANSOH PHARMA Falls 3.97% in Regular Trading, EU Revocation of Aumolertinib Approval Continues to Weigh on Sentiment
Market Focus  ·  10-02
Movement Alert｜HANSOH PHARMA Falls 3.97% in Regular Trading, EU Revocation of Aumolertinib Approval Continues to Weigh on Sentiment
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  09-30
Major Drugmakers Turn to China for Licensing Deals
Hansoh Pharmaceutical Group Stock Rises 5.3% in Hong Kong
Dow Jones  ·  09-30
Hansoh Pharmaceutical Group Stock Rises 5.3% in Hong Kong
No data available

Introduction

Company Name.
HANSOH PHARMA
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
Issue price:
--